On June 24, Hansoh Pharmaceutical rose 3.18% in regular trading, trading at 30.38 HKD/share, with turnover of approximately 180 million HKD.

On the news front, Guosheng Securities recently initiated coverage on Hansoh Pharmaceutical with a Buy rating and a target price of 40.61 HKD, implying a 37x P/E multiple and approximately 33% upside from current levels. Additionally, the company's self-developed GLP-1/GIP dual-target weight-loss drug Olebopatide has had its NDA accepted by China's NMPA for long-term weight management in obese or overweight adults. Phase III clinical data demonstrated a maximum weight reduction of 19.3% at 48 weeks with a nausea incidence below 10%, exhibiting strong efficacy and favorable tolerability. Related mechanistic research was also presented at the global endocrinology conference ENDO. The company reported full-year revenue of approximately RMB 15.03 billion, up 22.6% year-over-year, with net profit of RMB 5.56 billion, up 27.1%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)